Autor(es): Masrinoul Promsin, Puiprom Orapim, Tanaka Atsushi, Kuwahara Miwa, Chaichana Panjaporn, Ikuta Kazuyoshi, Ramasoota Pongrama, Okabayashi Tamaki

Resumo: Chikungunya virus (CHIKV) causes an acute clinical illness characterized by sudden high fever, intense joint pain, - skin rash. Recent outbreaks of chikungunya disease in Africa - Asia are a major public health concern; however, there is currently no effective licensed vaccine or specific treatment. This study reported the development of a mouse monoclonal antibody (MAb), CK47, which recognizes domain III within the viral envelope 1 protein - inhibited the viral release process, thereby preventing the production of progeny virus. The MAb had no effect on virus entry - replication processes. Thus, CK47 may be a useful tool for studying the mechanisms underlying CHIKV release - may show potential as a therapeutic agent.

Palavras-Chave: Chikungunya virus; Monoclonal antibody; Post-entry inhibitory step

Imprenta: Virology, v. 464-465, p. 111-117, 2014

Identificador do objeto digital: 10.1016/j.virol.2014.05.038

Descritores: Chikungunya virus - Pathogenesis ; Chikungunya virus - Proteins ; Chikungunya virus - Antibodies ; Chikungunya virus - Infectious diseases ; Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Chikungunya fever ; Chikungunya virus - Immunology ; Chikungunya virus - Public health

Data de publicação: 2014

INDICADORES

ACESSO